Ashan Berry Biotechnology (Shanghai) Co., Ltd.

Primary Objectives: To evaluate the dose-related safety and tolerability of oral ABI-H2158 in patients with chronic HBV (CHB) infection (Part 3); To evaluate changes in HBV DNA viral load in patients treated with ABI-H2158 (Part 3) Secondary Objectives: To evaluate the plasma PK of ABI-H2158 and its metabolites in CHB patients after single and multiple doses over 14 days (Part 3)

To evaluate the safety and tolerability of ABI-H2158 + ETV combination therapy in CHB subjects; To evaluate the effect of ABI-H2158 in reducing HBV DNA in CHB subjects

Primary Objective To evaluate the safety and tolerability of 731 combined with ETV±Peg-IFNα in the treatment of CHB subjects Secondary Objectives To evaluate the effect of 731 combined with ETV±Peg-IFNα in reducing HBV pgRNA levels in CHB subjects To evaluate the effect of 731 combined with ETV±Peg-IFNα in reducing HBV DNA levels in CHB subjects To evaluate the effect of 731 combined with ETV±Peg-IFNα in reducing HBV antigens (i.e., HBeAg, HBcrAg, and HBsAg) in CHB subjects To evaluate the effect of 731 combined with ETV±Peg-IFNα in restoring alanine aminotransferase (ALT) to normal To evaluate the PK of 731 in CHB subjects and the PK of Peg-IFNα and ETV in the future To evaluate the development of drug resistance when 731 is combined with ETV±Peg-IFNα